Psilocybin Therapy in Oregon: Promising Results Mixed With Safety Concerns and Accessibility Questions
Oregon’s licensed psilocybin centers show improved screening practices compared to dispensary models, but concerns remain about long-term safety, inconsistent follow-up, and the risk of treating mental health issues as recreational experiences. While some patients report benefits for depression and addiction, the lack of standardized pharmaceuticals raises questions about efficacy and control. The high cost—up to $1,900 per session—also highlights equity issues in emerging psychedelic treatments.
Since 2023, Oregon has operated licensed psilocybin service centers, requiring clients to be at least 21 years old and undergo preparation before consuming psilocybin under supervision at a facility—no take-home mushrooms are permitted. A 2026 study by Washington University in St. Louis found that while centers did ask about psychiatric history, medications like lithium, and suicidal ideation, the screening process remains non-clinical: no formal psychiatric diagnosis or evaluation is required, and facilitators need not be licensed mental health professionals. Among 346 adults receiving services, 92.2% reported benefits at one month, with improvements in depression, anxiety, PTSD, well-being, and life satisfaction by three months—though the study lacked a control group, limiting conclusions about causality. Four participants (1.2%) experienced serious adverse reactions requiring medical attention, including one violent episode and another who developed worsening symptoms and suicidal thoughts; alarmingly, only one of these incidents was reported in the official system. The lack of standardized pharmaceuticals, high cost—up to $1,900 per session—and absence of long-term follow-up raise concerns about safety, equity, and efficacy. The VA is preparing for potential FDA approval of psychedelic treatments for PTSD and depression, with up to 2.1 million veterans possibly benefiting, but delivery remains a challenge.
The broader context includes prior experiences with marijuana dis
Oregon’s psilocybin centers may influence national conversations about mental health treatment, particularly if they demonstrate long-term benefits without systemic oversight failures. The model could inspire similar state-level initiatives, but also raise concerns about commercialization and access disparities—especially given the $1,900 price tag, which may limit use to wealthier individuals. If adverse events go unreported or under-monitored, public trust in psychedelic therapies could erode, potentially slowing FDA approval processes for broader medical use. The VA’s interest suggests a possible future integration into veteran care, but only if safety and follow-up protocols are strengthened. A comparable precedent is the early days of medical marijuana, where initial enthusiasm was tempered by inconsistent regulation and quality control. What may unfold next includes increased scrutiny from federal agencies, pressure to standardize treatments through pharmaceutical development, an